Krajina: Izrael
Jazyk: angličtina
Zdroj: Ministry of Health
A/BRISBANE/02/2018(H1N1)PDM09-LIKE VIRUS; A/KANSAS/14/2017 (H3N2) LIKE VIRUS; B/COLORADO/06/2017- LIKE VIRUS (B/VICTORIA/2/87 LINEAGE); B/PHUKET/3073/2013 (B/YAMAGATA LINEAGE)-LIKE VIRUS
NEOPHARM SCIENTIFIC LTD
J07BB02
SUSPENSION FOR INJECTION
B/PHUKET/3073/2013 (B/YAMAGATA LINEAGE)-LIKE VIRUS 15 MCG / 0.5 ML; B/COLORADO/06/2017- LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) 15 MCG / 0.5 ML; A/KANSAS/14/2017 (H3N2) LIKE VIRUS 15 MCG / 0.5 ML; A/BRISBANE/02/2018(H1N1)PDM09-LIKE VIRUS 15 MCG / 0.5 ML
I.M, DEEP S.C.
Required
SEQIRUS VACCINES LTD, UK
INFLUENZA, PURIFIED ANTIGEN
INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN
Prophylaxis of influenza.
2019-09-08
SUMMARY OF PRODUCT CHARACTERISTICS AGRIPPAL™ S1 1. NAME OF THE MEDICINAL PRODUCT AGRIPPAL S1, Suspension for injection in pre-filled syringe Influenza Vaccine Surface Antigen, Inactivated (2017/2018 SEASON) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Influenza virus surface antigens (haemagglutinin and neuraminidase), of strains*: A/Michigan/45/2015 (H1N1)pdm09 -like strain (A/Singapore/GP1908/2015, IVR-180) 15 micrograms HA** A/Hong Kong/4801/2014 (H3N2)-like strain (A/Hong Kong/4801/2014, NYMC X-263B) 15 micrograms HA** B/Brisbane/60/2008-like strain (B/Brisbane/60/2008, wild type) 15 micrograms HA** * propagated in fertilized hens’ eggs from healthy chicken flocks ** haemagglutinin For one dose of 0.5ml This vaccine complies with the WHO recommendations (Northern Hemisphere) and EU decision for the 2017/2018 season. AGRIPPAL S1 may contain traces of eggs such as ovalbumin or chicken proteins, kanamycin and neomycin sulphate, formaldehyde, cetyltrimethylammonium bromide (CTAB), polysorbate 80 and barium sulphate which are used during the manufacturing process (see section 4.3). For a full list of excipients see section 6.1. 3. PHARMACEUTICAL FORM Suspension for injection in pre-filled syringe. The vaccine appears as a clear liquid. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prophylaxis of influenza, especially in those who run an increased risk of associated complications. AGRIPPAL S1 is indicated in adults and children from 6 months of age. The use of AGRIPPAL S1 should be based on official recommendations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Adults: 0.5 ml. _Paediatric population _ Children from 36 months onwards: 0.5 ml Children from 6 months to 35 months: Clinical data are limited. Dosages of 0.25 ml or 0.5 ml may be given. The dose given should be in accordance with the existing national recommendation. For children who have not previously been vaccinated, a second dose should be given after an interval of at least 4 weeks. Children less than 6 months: the safety and efficacy of Prečítajte si celý dokument